A 12-WEEK, PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER TRIAL IN OVERACTIVE BLADDER SUBJECTS TO CONFIRM THE EFFICACY OF 8 MG FESOTERODINE COMPARED TO 4 MG FESOTERODINE

Trial Profile

A 12-WEEK, PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER TRIAL IN OVERACTIVE BLADDER SUBJECTS TO CONFIRM THE EFFICACY OF 8 MG FESOTERODINE COMPARED TO 4 MG FESOTERODINE

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Fesoterodine (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Acronyms EIGHT
  • Sponsors Pfizer
  • Most Recent Events

    • 19 Feb 2014 Results published in the BJU International.
    • 24 Jan 2013 Results have been reported in a Pfizer media release.
    • 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top